Exomas develops exosome-based products that expand the cognitive reserve and induce neuronal plasticity to treat neurodegenerative diseases.
Exomas has raised $31K in total funding. The most recent round was Grant. The last funding was announced in July 2025.
Exomas's investors include Start-Up Chile, SF500.
Exomas is headquartered in Rosario, Argentina.
Exomas develops exosome-based products that expand the cognitive reserve and induce neuronal plasticity to treat neurodegenerative diseases.
Exomas is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exomas — Funding & Investors." VCBacked, July 18, 2025, https://www.vcbacked.co/company/exomas. Accessed August 14, 2026.
VCBacked. (2025). Exomas — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/exomas
{{cite web |title=Exomas — Funding & Investors |url=https://www.vcbacked.co/company/exomas |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated